G
Genovefa A. Papanicolaou
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 172
Citations - 8313
Genovefa A. Papanicolaou is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 36, co-authored 150 publications receiving 6934 citations. Previous affiliations of Genovefa A. Papanicolaou include Miriam Hospital & Brown University.
Papers
More filters
Journal ArticleDOI
Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database
Dimitrios P. Kontoyiennis,Kieren A. Marr,Benjamin J. Park,Barbara D. Alexander,Elias Anaissie,Thomas J. Walsh,James I. Ito,David R. Andes,John W. Baddley,Janice M. Brown,Lisa Brumble,Alison G. Freifeld,Susan Hadley,Loreen A. Herwaldt,Carol A. Kauffman,Katherine M. Knapp,G. Marshall Lyon,Vicki A. Morrison,Genovefa A. Papanicolaou,Thomas F. Patterson,Trish M. Perl,Mindy G. Schuster,Randall C. Walker,Kathleen A. Wannemuehler,John R. Wingard,Tom M. Chiller,Peter G. Pappas +26 more
TL;DR: In this national prospective surveillance study of IFIs in HSCT recipients, the cumulative incidence was highest for aspergillosis, followed by candidiasis, and understanding the epidemiologic trends and burden of IFI may lead to improved management strategies and study design.
Journal ArticleDOI
Determinants of COVID-19 disease severity in patients with cancer.
Elizabeth Robilotti,Elizabeth Robilotti,N. Esther Babady,Peter A. Mead,Peter A. Mead,Thierry Rolling,Rocio Perez-Johnston,Marilia Bernardes,Yael Bogler,Mario Caldararo,Cesar J. Figueroa,Cesar J. Figueroa,Michael S. Glickman,Michael S. Glickman,Alexa Joanow,Anna Kaltsas,Anna Kaltsas,Yeon Joo Lee,Yeon Joo Lee,Anabella Lucca,Amanda Mariano,Sejal Morjaria,Sejal Morjaria,Tamara Nawar,Genovefa A. Papanicolaou,Genovefa A. Papanicolaou,Jacqueline Predmore,Gil Redelman-Sidi,Gil Redelman-Sidi,Elizabeth K. Schmidt,Susan K. Seo,Susan K. Seo,Kent A. Sepkowitz,Kent A. Sepkowitz,Monika K. Shah,Monika K. Shah,Jedd D. Wolchok,Jedd D. Wolchok,Tobias M. Hohl,Tobias M. Hohl,Ying Taur,Ying Taur,Mini Kamboj,Mini Kamboj +43 more
TL;DR: Analysis of a large, single-center cohort of patients with cancer who were infected with COVID-19 uncovers factors associated with disease severity and interactions with anti-cancer therapies.
Journal ArticleDOI
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
Michael Boeckh,W. Garrett Nichols,Genovefa A. Papanicolaou,Robert H. Rubin,John R. Wingard,John A. Zaia +5 more
TL;DR: Primary CMV infection via blood transfusion can be reduced by the provision of seronegative or leukocyte-depleted blood products, and indirect immunomodulatory effects of CMV are increasingly recognized in hematopoietic stem cell transplant recipients.
Journal ArticleDOI
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.
Louis B. Rice,S. Willey,Genovefa A. Papanicolaou,A. A. Medeiros,George M. Eliopoulos,Robert C. Moellering,George A. Jacoby +6 more
TL;DR: Agarose gel electrophoresis of extracts from clinical isolates indicated that this outbreak arose from plasmid transmission among different strains of the family Enterobacteriaceae rather than from dissemination of a single resistant isolate.
Journal ArticleDOI
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Francisco M. Marty,Drew J. Winston,Scott D. Rowley,E.A. Vance,Genovefa A. Papanicolaou,Kathleen M. Mullane,Thomas M. Brundage,Alice Robertson,Susan Godkin,Herve Mommeja-Marin,Michael Boeckh +10 more
TL;DR: Treatment with oral CMX001 at a dose of 100 mg twice weekly significantly reduced the incidence of CMV events in recipients of hematopoietic-cell transplants.